VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NMRA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NMRANeumora Therapeutics, Inc. Common Stock
$0.37$68M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NMRA logo

Neumora Therapeutics, Inc. Common Stock

NMRA
NASDAQ · Neuroscience Biotech
$0.37
At close - Nov 16, 4:00 PM EST - USD
Market Cap$68M
P/E-0.4x
52W High$3.65
Volume1.49M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Challenges Neumora Liquidity Runway

Neumora Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on external capital to fund its precision psychiatry pipeline.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

NMRA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

6/12 Beats

EPS beat 6 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 2 · Lag

Laggard (Underperforming 98% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NMRA-77.74%
S&P 500 (^GSPC)+8.31%
1-Year Return
NMRA-85.73%
S&P 500 (^GSPC)+11.16%
3-Year Return
NMRA-96.92%
S&P 500 (^GSPC)+57.62%
5-Year Return
NMRA-97.73%
S&P 500 (^GSPC)+47.72%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$237M+2.8% YoY
Free cash flow FY25
-$206M-12.8% YoY
Operating margin FY25
-
ROIC (FY25)-527.4%
Avg ROIC 5Y-276%
ROE (TTM)-320.6%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate6/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
-$0.18+8.4%
vs -$0.20
$16,000
vs —
Q3 2026
Aug 14, 2026
-$0.23+4.2%
vs -$0.24
—
vs —
Q2 2026
May 7, 2026
-$0.30+6.3%
vs -$0.32
—
vs —
Q2 2026
Mar 16, 2026
-$0.35-2.9%
vs -$0.34
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

2 Stories
GlobeNewsWire·1d ago
Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration

Schaeffers Research·Sep 18, 2026
Biotech Options Buzz: UTHR, NMRA, EWTX

Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.

Filtered for Neumora Therapeutics, Inc. Common StockMore Headlines
04

Compare before deciding

Benchmark NMRA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Neumora Therapeutics, Inc. Common Stock (NMRA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NMRA logoNMRANeumora Therapeutics, Inc. Common StockCurrent
$0.37$68.46M-0.36—-1190187.5%-320.56%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.67$3.2B9.0411.87%30.13%28.03%—
INVA logoINVAInnoviva, Inc.
$18.49$1.36B6.8918.52%43.79%15.84%—
AXSM logoAXSMAxsome Therapeutics, Inc.
$137.01$7.05B-45.6865.55%-18.18%-189.73%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$310.27$8.65B-25.19-100%—-29.41%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.97$5.06B-48.03114.51%-9.17%——

Compare NMRA vs Peers

Neumora Therapeutics, Inc. Common Stock (NMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ACAD

Most directly comparable listed peer for NMRA.

Scale Benchmark

vs LLY

Larger-name benchmark to compare NMRA against a more recognizable public peer.

Peer Set

Compare Top 5

vs ACAD, INVA, AXSM, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

NMRA SEC Filings & Documents

Neumora Therapeutics, Inc. Common Stock (NMRA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 14, 2026·SEC

Material company update

Jul 27, 2026·SEC

Material company update

Jun 15, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 3, 2025·SEC

FY 2024

Mar 7, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 14, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

Get notified when NMRA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NMRA Frequently Asked Questions

Neumora Therapeutics, Inc. Common Stock (NMRA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Neumora Therapeutics, Inc. Common Stock's revenue?

Neumora Therapeutics, Inc. Common Stock (NMRA) reported $0.0M in revenue over the trailing twelve months.

Is NMRA profitable?

No. Neumora Therapeutics, Inc. Common Stock (NMRA) reported a net loss of $190.4M over the trailing twelve months.

Dividend & Returns
What is NMRA's return on equity?

Neumora Therapeutics, Inc. Common Stock (NMRA) had a return on equity (ROE) of -320.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Neumora Therapeutics, Inc. Common Stock's free cash flow?

Neumora Therapeutics, Inc. Common Stock (NMRA) had negative free cash flow of $167.3M over the trailing twelve months.

What if you invested $1,000 in NMRA back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →